ECE2013 Poster Presentations Thyroid (non-cancer) (100 abstracts)
1Department of Endocrinology and Metabolism, Dokuz Eylul University Medical School, Izmir, Turkey; 2Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey; 3Department of Allergy and Immunology, Celal Bayar University Medical School, Manisa, Turkey; 4Department of Biochemistry, Karsiyaka State Hospital, Izmir, Turkey.
Background: This study was planned to reveal the effect of propylthiouracil treatment on CD40, hs-CRP and Fetuin-A levels of subjects with subclinical hyperthyroidism.
Material and methods: After checking CD40, hs-CRP and Fetuin-A levels of 35 patients with subclinical hyperthyroidism, they were given 50 mg of propylthiouracil tablet (thrice daily). After the 3-month administration, CD40, hs-CRP and Fetuin-A levels were then compared to the levels before treatment.
Results: While hs-CRP and CD40 levels were found normal compared to the healthy controls in SHE patients, Fetuin-A levels were statistically significantly higher (*P=0.022). After the treatment, Fetuin-A levels of SHE patients decreased statistically significantly compared to the levels before treatment (**P=0.026). CD40 and hs-CRP levels did not revealed a statistically significantly difference compared to the control group and post levothyroxine treatment.
Conclusion: High Fetuin-A levels before propylthiouracil treatment and decrease in these levels after treatment in cases with subclinical hyperthyroidism indicated the possibility of preventing long-term cardiac complications with propylthiouracil treatment.
Key words: CD40, hs-CRP, Fetuin-A, subclinic hyperthyroidism.